BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/27/2024 10:57:13 AM | Browse: 157 | Download: 693
 |
Received |
|
2024-08-22 08:29 |
|
Peer-Review Started |
|
2024-08-06 11:19 |
|
First Decision by Editorial Office Director |
|
2024-09-19 02:04 |
|
Return for Revision |
|
2024-09-19 02:04 |
|
Revised |
|
2024-09-26 20:48 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-09-29 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-30 07:37 |
|
Articles in Press |
|
2024-09-30 07:37 |
|
Edit the Manuscript by Language Editor |
|
2024-10-05 21:56 |
|
Typeset the Manuscript |
|
2024-10-16 03:37 |
|
Publish the Manuscript Online |
|
2024-11-27 10:57 |
| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell & Tissue Engineering |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Evaluating Wharton’s jelly-derived stem cell therapy in autism: Insights from a case study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Muzamil Akhtar and Abdulqadir J Nashwan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abdulqadir J Nashwan, MSc, PhD, Research Scientist, Department of Nursing and Midwifery Research, Hamad Medical Corporation, Rayyan Road, Doha 3050, Qatar. anashwan@hamad.qa |
| Key Words |
Autism spectrum disorder; Stem cell therapy; Neuroinflammation; Neurodevelopmental disorders; Wharton jelly derived mesenchymal stem cell |
| Core Tip |
This letter highlights the groundbreaking study by Kabatas et al, which demonstrates the efficacy and safety of Wharton’s jelly-derived mesenchymal stem cell (WJ-MSC) therapy in improving developmental outcomes for a child with autism spectrum disorder. Despite limitations such as the single-case design and lack of a control group, the study suggests WJ-MSC therapy as a promising treatment option, emphasizing the need for larger, controlled trials to validate these findings and develop standardized treatment protocols. |
| Publish Date |
2024-11-27 10:57 |
| Citation |
Akhtar M, Nashwan AJ. Evaluating Wharton’s jelly-derived stem cell therapy in autism: Insights from a case study. World J Methodol 2025; 15(2): 100074 |
| URL |
https://www.wjgnet.com/2222-0682/full/v15/i2/100074.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v15.i2.100074 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
